P3 trial saving #COVID19-induced #ARDS patients. Extraordinary survival outcomes seen in pilot study (83% survival in ventilator-dependent patients w/ moderate/severe ARDS): https://buff.ly/2Ky4f3s More very soon.
This surely speaks to the inner confidence Mesoblast has and the effectiveness of the trial.Trial update must be imminent.
Cell Therapy News/Articles, page-4411
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.060(5.33%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.14 | $1.07 | $5.556M | 5.065M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 193123 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 300057 | 2 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.07 |
Change
-0.060 ( 5.22 %) |
||||
| Open | High | Low | Volume | ||
| $1.13 | $1.14 | $1.07 | 1328053 | ||
| Last updated 15.59pm 05/06/2024 ? | |||||
| MSB (ASX) Chart |